In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass dive into Novartis' (NYSE:NVS) recent earnings report, to give investors the key takeaways from the company this quarter.
The guys discuss how earnings were largely in line with expectations and note how the company's recent deal to acquire GlaxoSmithKline's (NYSE:GSK) early-stage oncology business while divesting itself of its vaccines business has made Novartis a more focused company. While David isn't terribly excited about the stock at the moment, the addition of this business to Novartis' own early stage oncology assets means that David does see the potential for outperformance here in the long run, for investors who are willing to wait.
David Williamson owns shares of Novartis. Michael Douglass and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Generic Drug Stocks to Consider Buying Now
Want to cash in on the pharmaceutical boom? Generic drugs add to the arguments for giving Pfizer, Novartis and Mylan a closer look.
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Here Are the Big Pharma Stocks to Own Based on R&D Spending
Roche, Novartis, Pfizer, Johnson & Johnson, and Merck are investing the heaviest in R&D. That could bode well for these big pharma stocks.